Eros Peptides Combines Three Drugs No Trial Has Tested Together

Eros is a compounded troche sold under one brand name that contains three separate drugs: tadalafil, PT-141 (bremelanotide), and oxytocin. Compounding pharmacies market it as a single sexual-health product. No published trial has tested that combination. What exists instead is three separate evidence bases of wildly different strength, stapled together inside one lozenge and sold as though they were one thing.

What the three ingredients’ trials tested

Start with tadalafil, because it is the only ingredient in Eros with the kind of evidence a prescriber would call solid. An integrated 2004 analysis pooled 11 randomized, placebo-controlled trials covering 2,102 men with mild-to-severe erectile dysfunction, dosed at fixed 10 mg or 20 mg on-demand doses. Men on tadalafil gained 6.5 to 8.6 points on the erectile-function domain of the IIEF over placebo, and the drug stayed effective up to 36 hours after dosing^[1]. That trial base is what earned tadalafil its FDA approval and its Cialis label, and it has nothing to do with PT-141 or oxytocin.

11 randomized placebo-controlled trials behind tadalafil, pooling over 2,000 men PMID 15180622

PT-141 (bremelanotide) rests on a narrower but still real trial base. Two identical phase 3 trials, RECONNECT, randomized 1,267 premenopausal women with hypoactive sexual desire disorder to a 1.75 mg subcutaneous injection or placebo over 24 weeks^[2]. Bremelanotide produced a statistically significant rise in desire scores, which is why the FDA approved it, under the brand Vyleesi, for that specific population and that specific injection. The magnitude of the change was modest in absolute terms even though the result was statistically real^[2].

Oxytocin brings the weakest and most contradictory record of the three. A 22-week, randomized, placebo-controlled crossover trial gave 30 pre- and postmenopausal women with sexual dysfunction either intranasal oxytocin (32 IU) or placebo before intercourse. Both arms improved on the Female Sexual Function Index, and there was no statistically significant difference between the two^[3]. Placebo matched oxytocin almost exactly, which is a more damning result for the drug than a trial that simply found a small effect.

Interventional evidence for the parts, none for the whole

All three ingredients come from interventional, randomized designs, the kind capable of supporting a causal claim about what each drug does alone. That distinction matters because it tells you what the evidence can and cannot support: a direct causal claim about tadalafil’s effect on erections, about bremelanotide’s effect on desire scores, about oxytocin performing the same as sugar water. None of those trials says anything about taking all three at once, because nobody has run that trial.

The closest the literature gets is a randomized crossover study that gave 19 men with erectile dysfunction a 7.5 mg dose of intranasal PT-141 alongside 25 mg of sildenafil, a different PDE5 inhibitor than the one in Eros. The combination produced a significantly larger RigiScan-measured erectile response than sildenafil alone, with no increase in adverse events^[4]. That is two of Eros’s three ingredients, in a different formulation, at different doses, paired with a different PDE5 inhibitor, and without oxytocin anywhere in the design. None of that stands in for evidence on Eros itself.

No trial has tested tadalafil, PT-141 and oxytocin together, in any formulation, at any dose, injected separately or combined into a single troche. The compounding pharmacies selling Eros are not hiding a trial that failed to find a benefit; no such trial has ever been run.

Three different receptor systems bundled into one lozenge

The gap matters at the mechanism level too. Each ingredient acts on a different system.

• Tadalafil inhibits phosphodiesterase type 5, the enzyme that normally breaks down cGMP in penile smooth muscle. Blocking that breakdown prolongs the nitric oxide-cGMP signal that sexual stimulation already triggers, keeping the muscle relaxed and the erection sustained^[5]. It amplifies a signal that already exists rather than creating one.
• PT-141 works upstream of that vascular pathway, in the brain. It agonizes melanocortin 4 receptors concentrated in the hypothalamus’s medial preoptic area, where animal data suggest it triggers dopamine release that raises desire itself^[6]. That is why it is studied for low libido rather than erectile mechanics: it tries to generate the signal that tadalafil can only amplify once it already exists.
• Oxytocin is proposed to work through a third system again, central oxytocin receptors tied to bonding and arousal. The clinical record for that mechanism is the thinnest of the three, consistent with the null result in the women’s crossover trial above.

Combining a PDE5 inhibitor with a central desire agent is at least mechanistically coherent, which is likely why researchers tested PT-141 alongside a PDE5 inhibitor in the first place. Mechanistic coherence is a hypothesis. It is not a result, and nobody has measured whether three receptor systems firing at once behave the way the sum of three separate trials would predict.

The dose problem: what was studied, what’s in the troche

Route and dose matter here, and Eros changes both.

What the trials tested versus what's in the troche

Route and dose as the trials published them, before compounding changes the delivery.

Tadalafil’s randomized trials, on-demand doses of 10 mg or 20 mg, or daily doses from 5 mg to 10 mg, were oral tablets swallowed whole, not dissolved under the tongue^[7]. Bremelanotide’s phase 3 trials dosed it as a 1.75 mg injection under the skin of the abdomen or thigh; nobody has published data on what happens when the same molecule is absorbed sublingually instead^[2]. Oxytocin’s own trials used a nasal spray. None of the three has a published sublingual pharmacokinetic profile, and a troche depends on buccal and sublingual absorption behaving the way injection or nasal delivery does. That is an assumption a compounding pharmacy is making on the patient’s behalf, and no published pharmacokinetic study backs it up.

Compounding pharmacies selling Eros also advertise the troche’s effect as lasting up to 48 hours. That figure does not appear in any tadalafil trial. The drug’s own trials, and the FDA label built from them, describe a window of up to 36 hours^[1]. Where the extra 12 hours comes from, or whether adding PT-141 and oxytocin extends the window at all, is not something any published study has measured.

Side effects: known separately, untested together

Each ingredient’s adverse-event profile comes from its own trials. Nobody has recorded what happens to a person taking all three at once.

• Tadalafil’s trials report headache, flushing, dyspepsia and back pain as the most common complaints, with rare but serious risks that include priapism and vision or hearing changes^[8].
• Bremelanotide’s integrated phase 3 safety data put nausea at 40.0% versus 1.3% on placebo, flushing at 20.3%, and injection site reactions at 5.4%. The trials also recorded small but statistically significant transient rises in blood pressure, enough that researchers now recommend caution and well-controlled blood pressure in anyone with cardiovascular risk^[9].

The interaction nobody has measured: tadalafil can lower blood pressure through vasodilation on its own, and bremelanotide can raise it transiently on its own. No published trial has tested what those two opposing effects do to each other inside the same dose, let alone with oxytocin added on top.

Where this leaves a man choosing between Eros and tadalafil alone

If a man’s problem is erectile function and nothing else, the trial base supporting tadalafil by itself dwarfs anything supporting Eros: multiple large placebo-controlled trials, decades of post-marketing data, an FDA label. The troche adds two more drugs whose evidence doesn’t transfer to him at all.

Bremelanotide’s own FDA approval covers premenopausal women with acquired, generalized hypoactive sexual desire disorder. No trial in its development program tested men for any indication^[2]. Selling it to men inside a troche stretches a regulatory approval across a sex and an indication its own trials never touched.

The pattern is a familiar one running backward. Minoxidil started life as a blood pressure drug and ended up sold for hair loss once researchers noticed an incidental side effect worth studying on its own terms, with its own trials, in the population that would use it. Eros skips that step. It takes a drug’s approval for one population’s desire disorder and applies it to a different population’s desire, with none of the intervening trial work repeated for the new audience.

What would have to happen before “it works” means anything

Settling whether Eros outperforms tadalafil alone, or whether it is simply tadalafil’s real effect carrying two inert passengers, would take a randomized trial comparing the full troche against tadalafil alone and against placebo in the same men. That trial does not exist. No version of it is registered in the public trial databases as of this writing.

Until someone runs it, every claim about what the combination adds beyond tadalafil’s own effect is a guess stitched out of three drugs that have never shared a dose. Why would anyone pay a compounding pharmacy extra for two unproven ingredients riding on an effect tadalafil already produces by itself?

This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.